Related Experiment Videos
Oral pindolol in acute evolving myocardial infarction
Abstract:
Pindolol was administered orally (5 mg 8th-hourly) to 30 patients 5--19 (mean = 9.0 hrs) hours after onset of acute myocardial infarction. There were no serious side effects during the acute phase of infarction, only one hospital death and two late deaths at follow-up 2--82 (mean = 37 wks) weeks after hospital discharge. In contrast to healthy volunteers, patients with acute infarction had unpredictable absorption of pindolol from the gastrointestinal tract; this was attributable in part to concurrent administration of narcotic analgesics.
Insights
Pindolol administration after acute myocardial infarction showed few side effects. However, drug absorption was unpredictable in patients, partly due to pain medications.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute myocardial infarction (AMI) is a critical condition requiring prompt management.
- Beta-blockers like pindolol are used in cardiovascular medicine.
- Understanding drug absorption in AMI patients is crucial for effective treatment.
Purpose of the Study:
- To assess the safety and efficacy of oral pindolol in patients experiencing acute myocardial infarction.
- To investigate the pharmacokinetic profile of pindolol in AMI patients compared to healthy individuals.
Main Methods:
- Oral pindolol (5 mg every 8 hours) was given to 30 patients within 5-19 hours of AMI onset.
- Patient outcomes, including side effects and mortality, were monitored during hospitalization and follow-up.
- Pindolol absorption was compared between AMI patients and healthy volunteers, considering concurrent medication use.
Main Results:
- No serious adverse events were observed during the acute phase of infarction.
- One in-hospital death and two late deaths occurred during follow-up (mean 37 weeks).
- Pindolol absorption was unpredictable in AMI patients, differing from healthy volunteers, partly due to narcotic analgesic use.
Conclusions:
- Pindolol appears safe for short-term use during the acute phase of myocardial infarction.
- Gastrointestinal absorption of pindolol is variable in AMI patients, influenced by factors like pain medication.
- Further research is needed to optimize pindolol dosing strategies in acute cardiac patients.